SCHEMBL2325110

SCHEMBL2325110

CCOP(=O)(O)CC(=O)c1cc(F)ccc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
ALDH1A1 P00352 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
EPHX2 P34913 2/20 0.34
PPARG P37231 2/20 0.34
FPR2 P25090 1/20 0.34
CES2 O00748 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
MRGPRX1 Q96LB2 2/20 0.34
SCD O00767 1/20 0.33
P2RX1 P51575 1/20 0.33
TMPRSS4 Q9NRS4 1/20 0.33
POLQ O75417 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550118 0.90 EPHX2 (0.39) KCNK3KCNK9ALDH1A1L3MBTL1HCRTR1
SCHEMBL1549852 0.86 HTT (0.41) MEN1LMNAKMT2ATMPRSS4POLQ
SCHEMBL2324778 0.84 CES2 (0.45) ALDH1A1CES2MEN1KMT2AMRGPRX1
SCHEMBL2324615 0.81 CES2 (0.45) ALDH1A1L3MBTL1CES2MEN1KMT2A
SCHEMBL2331699 0.81 RAB9A (0.40) KCNK3KCNK9ALDH1A1MEN1LMNA
SCHEMBL2325155 0.80 TSHR (0.36) ALDH1A1MEN1LMNAGAAKMT2A
SCHEMBL2325106 0.80 EPHX2 (0.38) KCNK3KCNK9HCRTR1HCRTR2EPHX2
SCHEMBL1549681 0.79 KMT2A (0.42) MEN1KMT2A
SCHEMBL27775801 0.77 KCNK3 (0.37) KCNK3KCNK9HCRTR1HCRTR2EPHX2
SCHEMBL26020578 0.77 CES2 (0.43) KCNK3KCNK9ALDH1A1L3MBTL1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 KCNK3 2881/4885KCNK9 3437/4885ALDH1A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.